BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$70.10 USD
-0.19 (-0.27%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $70.22 +0.12 (0.17%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth C Momentum B VGM
BioMarin Pharmaceutical (BMRN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$105.17 | $138.00 | $72.00 | 50.03% |
Price Target
Based on short-term price targets offered by 23 analysts, the average price target for BioMarin Pharmaceutical comes to $105.17. The forecasts range from a low of $72.00 to a high of $138.00. The average price target represents an increase of 50.03% from the last closing price of $70.10.
Analyst Price Targets (23)
Broker Rating
BioMarin Pharmaceutical currently has an average brokerage recommendation (ABR) of 1.48 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 25 brokerage firms. The current ABR compares to an ABR of 1.48 a month ago based on 25 recommendations.
Of the 25 recommendations deriving the current ABR, 19 are Strong Buy, representing 76% of all recommendations. A month ago, Strong Buy represented 76%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 19 | 19 | 19 | 18 | 17 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 6 | 6 | 6 | 7 | 8 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.48 | 1.48 | 1.48 | 1.56 | 1.64 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/19/2024 | Not Identified | Not Identified | Hold | Hold |
9/17/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
9/17/2024 | Evercore Partners | Cory Kasimov | Strong Buy | Strong Buy |
9/5/2024 | Truist Securities | Joon Lee | Strong Buy | Strong Buy |
9/5/2024 | Piper Sandler | Christopher Raymond | Strong Buy | Strong Buy |
9/3/2024 | Guggenheim Securities | Debjit Chattopadhyay | Strong Buy | Strong Buy |
8/30/2024 | William Blair | Sami Corwin | Not Available | Strong Buy |
8/20/2024 | Not Identified | Not Identified | Hold | Strong Buy |
8/6/2024 | Cowen & Co. | Philip M Nadeau | Strong Buy | Strong Buy |
8/6/2024 | Not Identified | Not Identified | Hold | Hold |
8/6/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/6/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/6/2024 | Not Identified | Not Identified | Hold | Hold |
8/6/2024 | Scotiabank | George Farmer | Hold | Hold |
8/5/2024 | Cantor Fitzgerald & Co | Olivia Brayer | Strong Buy | Strong Buy |
8/5/2024 | SVB Securities | Joseph P Schwartz | Strong Buy | Strong Buy |
7/25/2024 | Canaccord Genuity | Whitney Ijem | Hold | Hold |
6/27/2024 | Wells Fargo Securities | Mohit Bansal | Strong Buy | Strong Buy |
5/17/2024 | Robert W. Baird & Co. | Jack K Allen | Strong Buy | Hold |
4/1/2024 | BMO Capital Markets | Kostas Biliouris | Strong Buy | Strong Buy |
4/1/2024 | UBS | Eliana Merle | Strong Buy | Strong Buy |
3/29/2024 | Goldman Sachs | Salveen Richter | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.48 |
ABR (Last week) | 1.48 |
# of Recs in ABR | 25 |
Average Target Price | $105.17 |
LT Growth Rate | 36.10% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 77 of 252 |
Current Quarter EPS Est: | 0.79 |
BMRN FAQs
BioMarin Pharmaceutical Inc. (BMRN) currently has an average brokerage recommendation (ABR) of 1.48 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 25 brokerage firms.
The average price target for BioMarin Pharmaceutical Inc. (BMRN) is $105.17. The current on short-term price targets is based on 13 reports.
The forecasts for BioMarin Pharmaceutical Inc. (BMRN) range from a low of $72 to a high of $138. The average price target represents a increase of $50.03 from the last closing price of $70.10.
The current UPSIDE for BioMarin Pharmaceutical Inc. (BMRN) is 50.03%
Based on short-term price targets offered by 23 analysts, the average price target for BioMarin Pharmaceutical comes to $105.17. The forecasts range from a low of $72.00 to a high of $138.00. The average price target represents an increase of 50.03% from the last closing price of $70.10.